JP2009500427A5 - - Google Patents

Download PDF

Info

Publication number
JP2009500427A5
JP2009500427A5 JP2008520417A JP2008520417A JP2009500427A5 JP 2009500427 A5 JP2009500427 A5 JP 2009500427A5 JP 2008520417 A JP2008520417 A JP 2008520417A JP 2008520417 A JP2008520417 A JP 2008520417A JP 2009500427 A5 JP2009500427 A5 JP 2009500427A5
Authority
JP
Japan
Prior art keywords
group
disease
treating
medical condition
melanocortin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008520417A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009500427A (ja
JP4734411B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/026586 external-priority patent/WO2007008704A2/en
Publication of JP2009500427A publication Critical patent/JP2009500427A/ja
Publication of JP2009500427A5 publication Critical patent/JP2009500427A5/ja
Application granted granted Critical
Publication of JP4734411B2 publication Critical patent/JP4734411B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008520417A 2005-07-08 2006-07-10 メラノコルチン受容体リガンド Active JP4734411B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US69777905P 2005-07-08 2005-07-08
US60/697,779 2005-07-08
US74885005P 2005-12-09 2005-12-09
US60/748,850 2005-12-09
PCT/US2006/026586 WO2007008704A2 (en) 2005-07-08 2006-07-10 Melanocortin receptor ligands

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009263603A Division JP5889513B2 (ja) 2005-07-08 2009-11-19 メラノコルチン受容体リガンド

Publications (3)

Publication Number Publication Date
JP2009500427A JP2009500427A (ja) 2009-01-08
JP2009500427A5 true JP2009500427A5 (enExample) 2010-01-21
JP4734411B2 JP4734411B2 (ja) 2011-07-27

Family

ID=37637790

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2008520417A Active JP4734411B2 (ja) 2005-07-08 2006-07-10 メラノコルチン受容体リガンド
JP2009263603A Active JP5889513B2 (ja) 2005-07-08 2009-11-19 メラノコルチン受容体リガンド
JP2013165312A Pending JP2013253090A (ja) 2005-07-08 2013-08-08 メラノコルチン受容体リガンド
JP2015140154A Active JP5965520B2 (ja) 2005-07-08 2015-07-14 メラノコルチン受容体リガンド

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2009263603A Active JP5889513B2 (ja) 2005-07-08 2009-11-19 メラノコルチン受容体リガンド
JP2013165312A Pending JP2013253090A (ja) 2005-07-08 2013-08-08 メラノコルチン受容体リガンド
JP2015140154A Active JP5965520B2 (ja) 2005-07-08 2015-07-14 メラノコルチン受容体リガンド

Country Status (20)

Country Link
US (8) US8039435B2 (enExample)
EP (6) EP2236151B1 (enExample)
JP (4) JP4734411B2 (enExample)
KR (2) KR100997177B1 (enExample)
CN (5) CN101257916B (enExample)
AU (2) AU2006269261B2 (enExample)
CA (4) CA3228910A1 (enExample)
DK (4) DK2548568T3 (enExample)
ES (4) ES2604328T3 (enExample)
FR (1) FR21C1060I2 (enExample)
HU (4) HUE031731T2 (enExample)
IL (3) IL188545A (enExample)
NL (1) NL301150I2 (enExample)
NZ (2) NZ580806A (enExample)
PL (4) PL3354273T3 (enExample)
PT (4) PT2236151E (enExample)
RU (2) RU2380372C2 (enExample)
SG (1) SG163585A1 (enExample)
SI (1) SI3354273T1 (enExample)
WO (1) WO2007008704A2 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2236151B1 (en) * 2005-07-08 2012-05-23 Ipsen Pharma Melanocortin receptor ligands
DE102007020152A1 (de) * 2007-04-26 2008-10-30 Charité - Universitätsmedizin Berlin Mittel zur antiinfektiven Behandlung eines Patienten
RU2450017C2 (ru) 2007-05-25 2012-05-10 Ипсен Фарма С.А.С. Лиганды меланокортиновых рецепторов, модифицированные гидантоином
WO2008156677A2 (en) * 2007-06-15 2008-12-24 Ipsen Pharma S.A.S. Cyclic peptide melanocortin receptor ligands
CN103316345B (zh) * 2007-11-05 2016-05-18 益普生制药股份有限公司 黑皮质素治疗胰岛素敏感的应用
KR101810110B1 (ko) 2008-05-27 2017-12-18 젠자임 코포레이션 알파-멜라노사이트 자극 호르몬의 펩티드 유사체
CA2727317C (en) 2008-06-09 2015-02-17 Palatin Technologies, Inc. Melanocortin receptor-specific peptides for treatment of sexual dysfunction
CA2761607C (en) 2009-06-08 2018-09-04 Yi-Qun Shi Melanocortin receptor-specific peptides
EP2440572B1 (en) 2009-06-08 2017-04-05 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
AU2010279719A1 (en) * 2009-08-05 2012-03-01 Ipsen Pharma S.A.S. Use of melanocortins to treat dyslipidemia
CN102574894A (zh) * 2009-08-31 2012-07-11 张力控制股份有限公司 稳定化的黑皮质素配体
CN102665401A (zh) * 2009-11-16 2012-09-12 益普生制药股份有限公司 黑皮质素受体配体的药物组合物
RU2012125033A (ru) * 2009-11-16 2014-01-20 Ипсен Фарма С.А.С. СПОСОБ СИНТЕЗА Ас-Arg-ЦИКЛО(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2
BR112012011780A2 (pt) 2009-11-23 2019-09-24 Palatin Technologies, Inc peptídeo linear,composição farmacêutica,métodopara tratamento de umadoença,indicação,condição ou sídrome mediadsa por receptor de melanocortina emum mamífero humano ou não humano e método para tratamento de uma condição responsiva ás alterações em função de receptor de melanocortina em um mamifero humano ou não humano
AU2010321738B2 (en) 2009-11-23 2016-07-14 Palatin Technologies, Inc. Melanocortin-1 receptor-specific cyclic peptides
BR112013027222B1 (pt) 2011-06-14 2022-07-12 Ipsen Pharma S.A.S. Composição de liberação sustentada que contém peptídeos como ingrediente ativo
PL3539551T3 (pl) 2011-12-29 2022-02-21 Rhythm Pharmaceuticals, Inc. Sposób leczenia zaburzeń związanych z receptorem melanokortyny 4 u heterozygotycznych nosicieli
EP2705835A1 (en) 2012-06-08 2014-03-12 Ipsen Pharma S.A.S. Aqueous gelling compositions of soluble active pharmaceutical peptides providing modified release
AU2013333765B2 (en) 2012-10-19 2017-12-07 Txp Pharma Gmbh Alpha- and gamma-MSH analogues
WO2014153221A2 (en) 2013-03-14 2014-09-25 Questcor Pharmaceuticals, Inc. Acth for treatment of acute respiratory distress syndrome
AU2014227712B2 (en) 2013-03-15 2018-08-02 Rhythm Pharmaceuticals, Inc. Peptide compositions
EP2970389B1 (en) * 2013-03-15 2020-08-19 Rhythm Pharmaceuticals, Inc. Pharmaceutical compositions
HUE052977T2 (hu) 2014-04-22 2021-06-28 Txp Pharma Gmbh Elágazó szénláncú aminosav-próbával rendelkezõ peptid analóg(ok)
FI3356386T3 (fi) 2015-09-30 2024-05-16 Rhythm Pharmaceuticals Inc Melanokortiini-4-reseptoripolkuun liittyvien häiriöiden hoitamismenetelmä
US11542302B2 (en) 2015-10-15 2023-01-03 Arizona Board Of Regents On Behalf Of The University Of Arizona Modulators of melanocortin receptors for the treatment of depression and anxiety
US10653743B2 (en) * 2015-10-15 2020-05-19 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for the treatment of depression and anxiety by a melanocortin 5 receptor antagonist, PG-20N
US20190255142A1 (en) * 2016-10-17 2019-08-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Novel modulators of melanocortin receptors for the treatment of depression and anxiety
WO2018167194A1 (en) * 2017-03-15 2018-09-20 Novo Nordisk A/S Bicyclic compounds capable of binding to melanocortin 4 receptor
CA3096055A1 (en) 2018-04-06 2019-10-10 Rhythm Pharmaceuticals, Inc. Compositions for treating kidney disease
US20210221867A1 (en) * 2018-05-15 2021-07-22 Novo Nordisk A/S Compounds Capable of Binding to Melanocortin 4 Receptor
CN113260625A (zh) * 2018-05-23 2021-08-13 省卫生服务机构 用于成像或治疗的放射性标记的黑皮质素1受体特异性α-黑素细胞刺激激素类似物
US11396535B2 (en) 2019-03-01 2022-07-26 Provincial Health Services Authority Cyclic peptide analogs of melanocortin and amanitin and methods of making such
TW202228760A (zh) * 2020-09-24 2022-08-01 美商律森製藥股份有限公司 治療黑素皮質素-4受體路徑相關病症之方法
JP2024522348A (ja) * 2021-05-27 2024-06-18 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ｍｃ３ｒアゴニストペプチド
WO2024083843A1 (en) 2022-10-18 2024-04-25 Confo Therapeutics N.V. Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
WO2025123056A1 (en) * 2023-12-07 2025-06-12 Endevica Bio, Inc. Non-naturally occurring melanocortin analogs and associated methods

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US613874A (en) 1898-11-08 George e
US1613874A (en) 1922-03-29 1927-01-11 Miner Inc W H Friction draft gear
US5652214A (en) 1989-06-05 1997-07-29 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5595760A (en) 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5665702A (en) 1995-06-06 1997-09-09 Biomeasure Incorporated Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
US5916883A (en) 1996-11-01 1999-06-29 Poly-Med, Inc. Acylated cyclodextrin derivatives
SE9700620D0 (sv) 1997-02-21 1997-02-21 Wapharm Ab Cykliska peptider med selektivitet för MSH-receptor subtyper
US6350430B1 (en) 1997-10-27 2002-02-26 Lion Bioscience Science Ag Melanocortin receptor ligands and methods of using same
EP1076649A4 (en) 1998-04-28 2010-06-02 Trega Biosciences Inc ISOQUINOLINE-BASED COMPOUNDS IN PLACE OF MELANOCORTIN RECEPTOR LIGANDS AND METHODS OF USE
CN1193102C (zh) * 1998-07-27 2005-03-16 衣阿华州立大学研究基金会股份有限公司 黑皮质素－4受体基因及其作为动物脂肪含量、体重增加和/或饲料消耗的遗传标记的用途
AU775289B2 (en) 1998-08-21 2004-07-29 Children's Medical Center Corporation Use of melanin for inhibition of angiogenesis and macular degeneration
US6716810B1 (en) 1998-12-09 2004-04-06 Eleanor Roosevelt Institute Composition and method for regulation of body weight and associated conditions
US6603058B1 (en) 1998-12-09 2003-08-05 Oklahoma Medical Research Foundation Non-human animal model for obesity and uses thereof
BR0009497A (pt) 1999-03-29 2002-01-15 Procter & Gamble Ligantes de receptores de melanocortina
US6579968B1 (en) * 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
US7176279B2 (en) * 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
WO2003006620A2 (en) * 2001-07-11 2003-01-23 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptides
DE60040413D1 (de) 1999-11-12 2008-11-13 Merck & Co Inc Zellen mit defizientem melanocortin-3-rezeptor, transgene mäuse und verfahren zur auswahl von substanzen, die das körpergewicht regulieren können
US6600015B2 (en) 2000-04-04 2003-07-29 Hoffmann-La Roche Inc. Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity
AU2001260548A1 (en) * 2000-06-28 2002-01-08 Pfizer Products Inc. Melanocortin receptor ligands
US6720324B2 (en) 2000-07-05 2004-04-13 Synaptic Pharmaceutical Corporation Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof
AU2001292658A1 (en) 2000-09-13 2002-03-26 Eleanor Roosevelt Institute Method for treatment of insulin resistance in obesity and diabetes
US20030113263A1 (en) 2001-02-13 2003-06-19 Oregon Health And Sciences University, A Non-Profit Organization Methods and reagents for using mammalian melanocortin receptor antagonists to treat cachexia
JP2005511475A (ja) 2001-03-02 2005-04-28 ブリストル−マイヤーズ スクイブ カンパニー メラノコルチン受容体のモジュレーターとして有用な化合物及びそれを含む製薬組成物
US6770645B2 (en) * 2001-03-16 2004-08-03 Pfizer Inc. Pharmaceutically active compounds
US7034004B2 (en) * 2002-05-07 2006-04-25 University Of Florida Peptides and methods for the control of obesity
US20040128136A1 (en) * 2002-09-20 2004-07-01 Irani Pourang Polad Internet voice browser
CA2530024A1 (en) * 2003-06-19 2005-01-06 Eli Lilly And Company Melanocortin receptor 4(mc4) agonists and their uses
JP2006527772A (ja) * 2003-06-19 2006-12-07 イーライ リリー アンド カンパニー メラノコルチン３受容体（ｍｃ３ｒ）作用薬ペプチドの用途
US7084111B2 (en) 2003-06-23 2006-08-01 University Of Florida Research Foundation, Inc. Melanocortin receptor templates, peptides, and use thereof
WO2005019212A1 (en) * 2003-08-20 2005-03-03 Eli Lilly And Company Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide
ES2278346T3 (es) 2003-08-20 2007-08-01 Eli Lilly And Company Compuestos, procedimientos y formulaciones para suministro oral de un compuesto peptido (glp)-1 del tipo de glucagon o un peptido agonista (glp)-4 del receptor 4 de melacortina (mc4).
US20050192286A1 (en) * 2003-10-22 2005-09-01 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
DE10355559A1 (de) 2003-11-21 2005-06-23 Orthogen Ag Transskin
WO2005060985A1 (en) 2003-12-10 2005-07-07 Merck & Co., Inc. Inhibition of voluntary ethanol consumption with selective melanocortin 4-receptor agonists
EP1732586A1 (en) 2004-03-29 2006-12-20 Eli Lilly And Company Uses of melanocortin-4 receptor (mc4r) agonist peptides administered by continunous infusion
EP1812034A4 (en) 2004-10-08 2009-07-29 Clinuvel Pharmaceuticals Ltd COMPOSITIONS AND METHODS OF INDUCING MELANOESEES IN ONE PERSON
WO2006073771A2 (en) 2005-01-05 2006-07-13 Eli Lilly And Company Polyethylene glycol linked mc4r or mc3r agonist peptides
WO2006073772A1 (en) 2005-01-05 2006-07-13 Eli Lilly And Company Polyethylene glycol linked mc4r or mc3r agonist peptides
EP2236151B1 (en) * 2005-07-08 2012-05-23 Ipsen Pharma Melanocortin receptor ligands
SI1919947T1 (sl) 2005-08-26 2013-06-28 Abbvie Inc. Terapevtsko aktivni alfa-msh analogi

Similar Documents

Publication Publication Date Title
JP2009500427A5 (enExample)
JP2010090130A5 (enExample)
RU2009148318A (ru) Лиганды меланокортиновых рецепторов, модифицированные гидантоином
RU2008104803A (ru) Лиганды рецепторов меланокортинов
RU2401841C2 (ru) Лиганды рецепторов меланокортинов
TW200803862A (en) Compounds for modulating TRPV3 function
CN106170485B (zh) 对位取代的不对称脲及其医疗用途
JP2020100623A (ja) 炎症及び疼痛の治療のための組成物及び方法
WO2001022961A1 (en) New use of modafinil and the d/l enantiomer
US10604485B2 (en) Hydrobromide salt of N-(4-chloro-2-hydroxy-3-((3S)-3-piperidinylsulfonyl)phenyl-N′-(3-Fluoro-2-methylphenyl)urea
EA014942B1 (ru) Соль глюкуроновой кислоты и соединения пиперазина
CA2973746C (en) Prevention or treatment of uratic or gouty diseases
US20120238616A1 (en) Methods and compositions for treating sleep-related breathing disorders
CN108686213B (zh) 冷感觉通道激动剂在制备促进机体冷习服能力的药物中的应用
EP2451452B1 (en) Use of benzydamine in the treatment of p40-dependent diseases
CN114539130B (zh) 苯基哌嗪或苯基哌啶类化合物及其应用
CN106632198A (zh) 芳基乙醇胺槲皮素衍生物及其制备方法和用途
RU2412184C2 (ru) Соли производного пиперазина с салициловой и гентизиновой кислотами
JP2009507923A (ja) 持続放出製剤およびこれの使用
CN101677556A (zh) 治疗cb2受体介导的疼痛的方法
CN106474113A (zh) 一种用于缺血性脑卒中后神经再生的药物组合物及其应用
CN104208507B (zh) 一种防治小儿惊风的穴位外敷膏
CN105055409A (zh) 一种治疗缺血性脑损伤药物及其应用
TW201517903A (zh) 便秘症之預防或治療藥
WO2022004788A1 (ja) 代謝異常を伴う疾患又は症候群における筋力低下症状の改善剤又は予防剤